Cobalamin‐Related Remethylation Disorders: Pregnancy Outcomes and Prenatal Treatment‐New Cases and a Literature Study

Cobalamin-related remethylation disorders (cbl-RD) are rare, heterogenous conditions with a wide phenotypic spectrum, including prenatal and early infantile manifestations. Data on pregnancy outcomes in affected women and the efficacy and safety of prenatal treatment of affected fetuses remain limited. Here we report (1) five women with cbl-RDs (3 cblC/epi-cblC, 1 cblD, 1 cblE) who had in total nine pregnancies and (2) eight fetuses with cbl-RD (7 cblC, 1 cblF) diagnosed and treated prenatally. All affected mothers were treated with hydroxocobalamin (OHCbl) during pregnancy and two also received betaine and carnitine. Complications included three preterm deliveries and nephrotic-range proteinuria in one previously undiagnosed mother with cblE. All offspring had favourable outcomes. In pregnancies with affected fetuses, OHCbl was administered to the mother between gestational weeks 5 and 32 at varying doses. Prenatally treated cblC cases exhibited attenuated phenotypes without microcephaly, epilepsy, or severe multisystemic disease. Notably, three of five infants harbouring severe MMACHC variants, who received high-dose pre- and postnatal OHCbl, exhibited normal neurodevelopment and no maculopathy up to age 2-3 years, though variability in genotype, treatment regimens, and duration of follow-up limit generalizability. A literature review identified nine additional pregnancies in women with cbl-RD and seven prenatally treated fetuses, with follow-up available for three. Collectively, our main findings support the safety of maternal and fetal OHCbl treatment during pregnancy. We recommend that when combined with preconception counselling, early standardized diagnosis, optimal monitoring and postnatal care, prenatal OHCbl therapy can improve pregnancy outcomes and mitigate neurodevelopmental and ophthalmic complications in cbl-RD.

Authors

Institutions

Publication Details

Journal
Journal of Inherited Metabolic Disease
Published
2026-08-26
DOI
https://doi.org/10.1002/jimd.70243
Primary Topic
Folate and B Vitamins Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Cobalamin‐Related Remethylation Disorders: Pregnancy Outcomes and Prenatal Treatment‐New Cases and a Literature Study

Karolina M. Stępień, Manuel Schiff, Wadih M. Zein, Louise Lapagesse et al.
Journal of Inherited Metabolic Disease
Folate and B Vitamins Research
article

Cobalamin‐Related Remethylation Disorders: Pregnancy Outcomes and Prenatal Treatment‐New Cases and a Literature Study

Karolina M. Stępień, Manuel Schiff, Wadih M. Zein, Louise Lapagesse, Amanda Krzywdzińska, Ida Vanessa Döederlein Schwartz, Martina Huemer, Sarah L. Bick, Pavel Ješina, Charles P. Venditti, Apolline Imbard, Audrey Thurm, Fanny Mochel, Irini Manoli, Carol Van Ryzin, Nina B. Gold, Jennifer L. Sloan, Mirian C. H. Janssen, Flávia Piazzon, Lisa Joseph, Juliette Bouchereau, Jolanta Sykut‐Cegielska, Edwin C. Ferren
article en

Abstract

Cobalamin-related remethylation disorders (cbl-RD) are rare, heterogenous conditions with a wide phenotypic spectrum, including prenatal and early infantile manifestations. Data on pregnancy outcomes in affected women and the efficacy and safety of prenatal treatment of affected fetuses remain limited. Here we report (1) five women with cbl-RDs (3 cblC/epi-cblC, 1 cblD, 1 cblE) who had in total nine pregnancies and (2) eight fetuses with cbl-RD (7 cblC, 1 cblF) diagnosed and treated prenatally. All affected mothers were treated with hydroxocobalamin (OHCbl) during pregnancy and two also received betaine and carnitine. Complications included three preterm deliveries and nephrotic-range proteinuria in one previously undiagnosed mother with cblE. All offspring had favourable outcomes. In pregnancies with affected fetuses, OHCbl was administered to the mother between gestational weeks 5 and 32 at varying doses. Prenatally treated cblC cases exhibited attenuated phenotypes without microcephaly, epilepsy, or severe multisystemic disease. Notably, three of five infants harbouring severe MMACHC variants, who received high-dose pre- and postnatal OHCbl, exhibited normal neurodevelopment and no maculopathy up to age 2-3 years, though variability in genotype, treatment regimens, and duration of follow-up limit generalizability. A literature review identified nine additional pregnancies in women with cbl-RD and seven prenatally treated fetuses, with follow-up available for three. Collectively, our main findings support the safety of maternal and fetal OHCbl treatment during pregnancy. We recommend that when combined with preconception counselling, early standardized diagnosis, optimal monitoring and postnatal care, prenatal OHCbl therapy can improve pregnancy outcomes and mitigate neurodevelopmental and ophthalmic complications in cbl-RD.

Journal of Inherited Metabolic DiseaseVol. 49(5)
Hôpital Necker-Enfants Malades (FR), Seattle Children's Hospital (US), National Institutes of Health (US), Universidade Federal do Rio Grande do Sul (BR), Children’s Institute (US), Harvard University (US), Radboud University Nijmegen (NL), Inserm (FR), University of Washington (US), Université Paris Cité (FR), Charles University (CZ), Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR), Radboud University Medical Center (NL), Sorbonne Université (FR), Massachusetts General Hospital (US), National Human Genome Research Institute (US), Hospital de Clínicas de Porto Alegre (BR), Assistance Publique – Hôpitaux de Paris (FR), Hôpital d'Enfants (FR), Salford Royal Hospital (GB), Pitié-Salpêtrière Hospital (FR), CEA Paris-Saclay (FR), University Children's Hospital Zurich (CH), Hospital Infantil Joana de Gusmão (BR), LKH Hochsteiermark (AT), National Eye Institute (US), Institut de Biologie et Technologies (FR), National Institute of Mental Health (US), General University Hospital in Prague (CZ), Hôpital de la Timone (FR), Institut des Maladies Génétiques Imagine (FR), Wake Forest University (US), Vorarlberg University of Applied Sciences (AT)
U.S. Department of Health and Human Services, National Institutes of Health
Good health and well-being
Openalex Percentile: Top 9%
Folate and B Vitamins Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.